Hematology

Venclexta is designed to trigger a natural process that helps cells self-destruct in chronic lymphocytic leukemia (CLL).

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

Experimental drug could may lead to new treatments for AML, lung cancer, brain cancer, and melanoma.

Approval of first oral proteasome inhibitor, ixazomib (Ninlato), may ease treatment burden for multiple myeloma.

A new pill makes all-oral therapy possible for patients with multiple myeloma.

Plitidepsin (Aplidin) in combination with dexamethasone found to reduce risk of progression and death from multiple myeloma.

Plitidepsin (Aplidin) in combination with dexamethasone shows 35% reduction in the risk of progression or death over comparator drug in multiple myeloma.

Research considers the importance of immunity in regulating the transformation from myelodysplastic syndrome to acute myeloid leukemia.

Stimulator of interferon gene agonists may offer hope in the treatment of in lymphoma, multiple myeloma, and certain forms of leukemia.

Promising study may lead to targeted treatment for patients with ALL.

Study estimates health insurers can save $9.1 million over 5 years per 100 CML patients.

Researchers seek to develop drugs that are less toxic and achieve longer remissions in multiple myeloma patients.

Gene overexpressed in AML may offer new target for halting the spread of cancer.

Preclinical studies of a combination therapy with birinapant and p38 inhibitors show promise treating AML.

Evomela is the first drug approved for a high-dose conditioning indication of multiple myeloma.

Evomela is the first product to be FDA-approved for a high-dose conditioning indication for multiple myeloma.

Radiotherapy and panobinostat show promise treating glioblastoma.

The Leukemia & Lymphoma Society and Walgreens have announced the launch of an innovative collaboration designed to further advance cancer therapies and address the changing treatment model facing patients with blood and other cancers.

New chemoimmunotherapy drugs found to improve survival in patients with CLL.

Combination therapy with lenalidomide and dexamethasone plus bortezomib in multiple myeloma patients shows significant improvement.

A study found positive outcomes of dose-attenuated combination therapy with lenalidomide and dexamethasone plus bortezomib in multiple myeloma patients.

The cost of treating pediatric cancer can force higher-income families into poverty.

The FDA has approved Janssen Biotech's ibrutinib capsules for treatment-naïve patients with chronic lymphocytic leukemia.

Caregivers should closely monitor hepatitis C infection in patients undergoing chemotherapy.

ONC201 caused p53-independent cell death and cell cycle arrest in lymphoma and acute leukemia patient samples.

Ibrutinib (Imbruvica) is the first FDA-approved chemotherapy-free treatment for patients with chronic lymphocytic leukemia (CLL).

Ibrutinib (Imbruvica) is the first chemotherapy-free treatment for first line CLL patients approved by the FDA.

The application includes new data for pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Blincyto is currently the only FDA-approved bispecific CD19-directed CD3 T cell engager immunotherapy available for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.